Vaxart Defends Board Amid Shareholder Proxy Fight
Event summary
- Vaxart filed preliminary proxy materials for its July 16, 2026 Annual Meeting of Stockholders.
- The company issued an open letter to shareholders defending its board against dissident shareholder nominations.
- Vaxart has $61 million in cash, providing runway into Q2 2027.
- Phase 2b COVID-19 trial data from the sentinel cohort expected in Q2 2026.
- Dr. James Breitmeyer added to the board, bringing 35 years of clinical and regulatory experience.
The big picture
Vaxart is at a critical juncture, defending its board while advancing its oral vaccine platform. The company's financial resilience and strategic partnerships, such as with BARDA and Dynavax (now part of Sanofi), are key to navigating the challenging biotech funding environment. The outcome of the proxy fight and the success of its clinical trials will determine its ability to create shareholder value.
What we're watching
- Governance Dynamics
- Whether Vaxart can maintain board control amid dissident shareholder pressure.
- Clinical Milestones
- The pace at which Vaxart can deliver positive data from its Phase 2b COVID-19 trial.
- Financial Sustainability
- How Vaxart will manage its cash runway into Q2 2027 and secure additional funding.
Related topics